Caplin Point Laboratories Limited has informed the Exchange regarding 'Submission of copy of Financial Results'.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories reported strong FY25 results with consolidated revenue from operations of ₹1,937.47 Crores, up 14.4% YoY, and total revenue of ₹2,033.90 Crores (+15.5%). Consolidated PAT grew 17.3% to ₹541.09 Crores, with EBITDA margin expanding to 36.5% from 35.1% and EPS rising 17.2% to ₹70.57. Cash flow from operations nearly doubled to ₹432.37 Crores, and the company holds ₹1,180 Crores in free cash reserves. On the standalone basis, revenue grew 20.4% to ₹752.41 Crores with PAT of ₹339.49 Crores (+19.7%). The Board declared an interim dividend of ₹3.00 (150%) per share of face value ₹2, with May 30, 2025 as the record date. The statutory auditor issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong double-digit growth in revenue, profits, and margins, combined with a generous 150% interim dividend and clean audit opinion, signals robust financial health and is likely to be viewed positively by shareholders. The company's strong cash generation and liquid assets of ₹2,148 Crores provide a solid foundation for future growth investments.